News
INSM
74.54
+0.05%
0.04
ClearBridge SMID Cap Growth Strategy Q2 2024 Commentary
ClearBridge SMID Cap Growth Strategy underperformed its benchmark in the second quarter of 2024. The Russell 1000 Index returned 3.57% and the Russell 2500 Growth Index returned 4.28%. Growth stocks held up only marginally better than their value counterparts. Bouts of volatility and contradictory signals around the health of the economy led to retreat in SMID stocks.
Seeking Alpha · 21h ago
IWM, HEJD: Big ETF Inflows
NASDAQ · 1d ago
Artisan Mid Cap Fund Q2 2024 Commentary
Seeking Alpha · 3d ago
3 Top ETFs to Add Small-Cap Stock Exposure
Federal Reserve is expected to cut interest rates in September. The low inflation rate is good news for small-cap stocks. The iShares Core S&P Small-Cap and iShares Russell 2000 ETFs are three top ETFs for investors to gain exposure to small-caps.
Barchart · 4d ago
Weekly Report: what happened at INSM last week (0715-0719)?
Weekly Report · 4d ago
Exploring Insmed's Key Growth Drivers...
NASDAQ · 5d ago
Russell rotation: YTD market capitalizations swelling for small-caps
Russell 2000 rose for a second straight week, picking up 1.5%. Small-caps funds drew in $9.9B over the past week, the second-largest weekly inflow on record. Insmed is among the Russell 2000 constituents posting big jumps in stock-price performances. Small-cap stocks are seeing billions of dollars added to their year-to-date market caps.
Seeking Alpha · 07/19 22:08
IWM, AIPI: Big ETF Inflows
NASDAQ · 07/17 16:24
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary. Small cap stocks are enduring their largest period of underperformance versus large caps to start a year in the last 51 years. Volatility in the Russell 2000 Growth Index was only down 2.9% in the second quarter of 2024.
Seeking Alpha · 07/17 14:40
Looking Into Insmed's Recent Short Interest
Insmed's short percent of float has risen 10.99% since its last report. The company has 12.83 million shares sold short, which is 7.98% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered. Short selling is when a trader sells shares of a company and hopes the price will fall.
Benzinga · 07/16 13:45
Weekly Report: what happened at INSM last week (0708-0712)?
Weekly Report · 07/15 09:13
Rivian Automotive & Baidu Are Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 7-July 13): Are The Others In Your Portfolio?
Rivian Automotive Inc stock gained 21.37% in the last week following recent CPI Data. Shares of homebuilders, building companies and housing-related companies gained as Treasury yields dropped following softer-than-expected June CPI figures. Baidu, Inc. Stock escalated 11.80% on reports of growing interest in its robotaxi service in China.
Benzinga · 07/14 14:34
Insmed Is Maintained at Overweight by Morgan Stanley
Dow Jones · 07/12 17:12
Insmed Price Target Raised to $85.00/Share From $60.00 by Morgan Stanley
Dow Jones · 07/12 17:12
Morgan Stanley Maintains Overweight on Insmed, Raises Price Target to $85
Benzinga · 07/12 17:02
Validea Detailed Fundamental Analysis - INSM
NASDAQ · 07/12 16:10
Morgan Stanley Sticks to Its Buy Rating for Insmed (INSM)
TipRanks · 07/12 12:26
Barclays Keeps Their Buy Rating on Insmed (INSM)
TipRanks · 07/12 08:17
Insmed Price Target Raised to $102.00/Share From $74.00 by Goldman Sachs
Dow Jones · 07/10 15:37
Insmed Is Maintained at Buy by Goldman Sachs
Dow Jones · 07/10 15:37
More
Webull provides a variety of real-time INSM stock news. You can receive the latest news about Insmed Inc through multiple platforms. This information may help you make smarter investment decisions.
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).